David Ricks, CEO and President of Eli Lilly and Company (LLY), recently picked up 4,615 shares. At a cost of $500,000, the buy increased his stake by nearly 3 percent.

On the same day, Director Jackson Tai bought 1,861 shares at a slightly lower price, shelling out $200,000 in total. These buys are the first following a series of sales in September by a number of officers and an endowment that is also a major holder of shares.

Eli Lilly is a developer and manufacturer of pharmaceutical products worldwide, with various products and vaccines for human and animal use. As part of the out-of-favor healthcare sector where insiders keep buying, shares have lagged the S&P 500 by 12 points in the past year.